REGN Add to watchlist
$663.09 +0.00 (+0.00%)
Pre-Market: $656.12 6.97 (-1.05%)
Last updated: Jul 15, 2026 09:22
52-Week Range
$656.12
$541.00 $656.12 $821.11

Fundamentals Overview

Regeneron Pharmaceuticals, Inc. is in the middle of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 16 P/B 2.17 P/S 4.53

Intrinsic value (DCF)

+254.9% upside vs price

Profitability

Net margin 29.6%

Risk (Beta)

0.24 — lower vol

Earnings & growth

EPS $41.07 Rev -7.2% Profit -13.9% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 56% confidence Risk: Lower Volatility — Beta 0.24. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +254.9% upside vs price · Analyst grade: A

Pressures (Sell):

Sentiment weakening (2 downgrades) · 3M vs S&P 500: -21.7% · 3M vs Healthcare sector: -19.1%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$67.59B
P/E (TTM)
15.98
EPS (TTM)
$41.07
Dividend Yield
0.55%
52-Week Range
$541.00 - $821.11
Volume vs Avg
N/A
Beta
0.24

About

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both ce...
Sector: Healthcare
Headquarters: US
Employees: 15,410
IPO Date: Apr 1991
Beta: 0.24 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 11, Equal Weight: 5, Market Perform: 1, Neutral: 1, Outperform: 2, Overweight: 6, Sector Perform: 4.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $2,328.36; current price is $656.12. That’s a +254.9% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 15.98
DCF value (model) $2,328.36 (254.9% upside)
PEG (TTM) N/A
P/B (TTM) 2.17
P/S (TTM) 4.53
P/FCF (TTM) 16.27
Liquidity & enterprise
Current Ratio (TTM) 3.57
Quick Ratio (TTM) 2.96
Cash Ratio (TTM) 0.58
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 29.65%
Gross margin (TTM) 84.55%
Operating margin (TTM) 24.32%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for REGN.

Analyst Sentiment at a Glance

A Sentiment Weakening
Buy 11Equal Weight 5Market Perform 1Neutral 1Outperform 2Overweight 6Sector Perform 4
1 upgrade, 2 downgrades
Price Target Consensus
Current $656.12
Median $839.50
Consensus $823.11
Low consensus $641.00
High consensus $995.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Piper Sandler maintain Overweight Overweight 2026-07-09
Morgan Stanley maintain Equal Weight Equal Weight 2026-07-08
Truist Securities maintain Buy Buy 2026-07-07
Benchmark upgrade Hold Buy 2026-07-07
RBC Capital maintain Sector Perform Sector Perform 2026-07-07
HSBC maintain Buy Buy 2026-07-06
Cantor Fitzgerald maintain Overweight Overweight 2026-07-06
Canaccord Genuity maintain Buy Buy 2026-05-19
Citigroup downgrade Buy Neutral 2026-05-18
Piper Sandler maintain Overweight Overweight 2026-05-18
Wells Fargo maintain Equal Weight Equal Weight 2026-05-18
Leerink Partners downgrade Outperform Market Perform 2026-05-18
JP Morgan maintain Overweight Overweight 2026-05-18
RBC Capital maintain Sector Perform Sector Perform 2026-05-18
Truist Securities maintain Buy Buy 2026-05-18
BMO Capital maintain Outperform Outperform 2026-05-18
Guggenheim maintain Buy Buy 2026-05-01
Barclays maintain Overweight Overweight 2026-04-30
RBC Capital maintain Sector Perform Sector Perform 2026-04-30
Wells Fargo maintain Equal Weight Equal Weight 2026-04-30
Truist Securities maintain Buy Buy 2026-04-30
TD Cowen maintain Buy Buy 2026-04-23
Cantor Fitzgerald maintain Overweight Overweight 2026-04-23
Morgan Stanley maintain Equal Weight Equal Weight 2026-04-10
Bernstein maintain Outperform Outperform 2026-04-08
Truist Securities maintain Buy Buy 2026-03-31
RBC Capital maintain Sector Perform Sector Perform 2026-03-02
Guggenheim maintain Buy Buy 2026-02-09
Morgan Stanley maintain Equal Weight Equal Weight 2026-02-02
Truist Securities maintain Buy Buy 2026-02-02